MBRC-401

MBRC-401 is a preclinical-stage antibody-drug conjugate (ADC) being developed by MBrace Therapeutics for the treatment of cancer. The candidate was identified and developed using MBrace's proprietary SPARC (Selection of Phage-displayed Antibody-Repertoire Libraries on Cells) platform, which is designed to discover novel tumor-specific targets and antibodies that are efficiently internalized by cancer cells. While the specific molecular target and cytotoxic payload for MBRC-401 have not been publicly disclosed, the agent is part of a broader pipeline of next-generation ADCs intended to treat solid tumors with high unmet medical needs. As a preclinical asset, it represents the early-stage expansion of the company's oncology portfolio following their lead clinical programs.